Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02684032
What this trial is testing

Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Celcuity Inc 141
Early research (Phase 1)Study completedNCT01238952
What this trial is testing

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 4
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Testing effectiveness (Phase 2)Study completedNCT03633331
What this trial is testing

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
Alliance for Clinical Trials in Oncology 93
Testing effectiveness (Phase 2)Study completedNCT03691493
What this trial is testing

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+4 more
Emory University 36
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Early research (Phase 1)Active Not RecruitingNCT05293964
What this trial is testing

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 214
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Post-approval studies (Phase 4)Active Not RecruitingNCT05486182
What this trial is testing

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 153
Large-scale testing (Phase 3)Active Not RecruitingNCT04158362
What this trial is testing

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Who this might be right for
Cancer Metastatic
UNICANCER 180
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Study completedNCT01307891
What this trial is testing

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast CancerStage IV Breast Cancer+1 more
University of Alabama at Birmingham 64
Testing effectiveness (Phase 2)Ended earlyNCT00517361
What this trial is testing

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University of Chicago 11
Testing effectiveness (Phase 2)WithdrawnNCT03841747
What this trial is testing

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Queen Mary University of London
Not applicableStudy completedNCT03195192
What this trial is testing

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Side-Out Foundation 28
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Large-scale testing (Phase 3)Ended earlyNCT05065411
What this trial is testing

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Veru Inc. 5
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)WithdrawnNCT04901299
What this trial is testing

Fulvestrant + Neratinib In Breast Cancer

Who this might be right for
Stage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast Cancer+3 more
Massachusetts General Hospital
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Next Page